BOTTOM LINE: Our primary strategic objective must be to prevent ICU overwhelm, which is imminent in many US cities on our current course. It is an axiom of infectious diseases that treatment in earlier stages is more effective than treating advanced stages. Early COVID-19 treatment is more likely to prevent disease progression to critical status, which could radically lower hospitalizations and Case Fatality Rate (CFR). Current clinical drug trials are mostly focused on treating late stages of disease, when immunologic damage becomes a dominant threat.